Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23212046 | 0.89 | MMP13 (0.53) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL31668220 | 0.85 | DPP4 (0.53) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL21381612 | 0.85 | MMP13 (0.52) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL23211814 | 0.85 | MMP13 (0.52) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL23211854 | 0.84 | MMP13 (0.51) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL5705714 | 0.84 | MMP13 (0.56) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL23212019 | 0.83 | MMP13 (0.49) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL5940502 | 0.83 | MMP13 (0.52) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL21384665 | 0.82 | MMP13 (0.48) | MMP13GPR119DPP4MEN1KMT2A | |
| SCHEMBL31668194 | 0.81 | MMP13 (0.48) | MMP13GPR119DPP4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517894-B1 | N-BENZYL-3-PHENYL-3-HETEROCYCLYL-PROPIONAMIDE COMPOUNDS AS TACHYKININ ANTAGONISTS AND/OR SEROTONIN REUPTAKE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-09-06 | — | — | EP | disclosed |
| US-20060058348-A1 | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058348-A1 | N-benzyl-3-phenyl-3-heterocyclyl-propionamide compounds as tachykinin and/or serotonin reuptake inhibitors | HTR7, OPRL1, HCRTR1 | MMP13 3498/4885GPR119 677/4885DPP4 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.